[{"id":"ace74252-54a3-493a-b223-6a52f7db4913","acronym":"","url":"https://clinicaltrials.gov/study/NCT06770452","created_at":"2025-02-26T06:54:41.243Z","updated_at":"2025-02-26T06:54:41.243Z","phase":"Phase 2","brief_title":"HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","source_id_and_acronym":"NCT06770452","lead_sponsor":"Zhejiang University","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab) • HRS-4642"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-01-13"},{"id":"88bf7c40-1a30-459a-8693-a4d5d65c020b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06587061","created_at":"2025-02-26T14:52:08.919Z","updated_at":"2025-02-26T14:52:08.919Z","phase":"Phase 2","brief_title":"HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","source_id_and_acronym":"NCT06587061","lead_sponsor":"Ruijin Hospital","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • HRS-4642"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-09-19"},{"id":"07acdaee-81fa-42a2-b6a8-44ffa1343ca1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06385678","created_at":"2024-04-26T18:53:22.008Z","updated_at":"2024-07-02T16:35:07.335Z","phase":"Phase 1/2","brief_title":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","source_id_and_acronym":"NCT06385678","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • AiRuiLi (adebrelimab) • HRS-4642 • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-04-26"},{"id":"b981fcae-ee9d-4262-ac3e-1cf908d11d83","acronym":"","url":"https://clinicaltrials.gov/study/NCT05533463","created_at":"2022-09-09T15:54:57.974Z","updated_at":"2024-07-02T16:35:30.238Z","phase":"Phase 1","brief_title":"Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","source_id_and_acronym":"NCT05533463","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRS-4642"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-11-06"}]